News

Despite advancements in melanoma therapy, the prognosis remains unfavorable for many patients. The proteasome inhibitor MG132 has shown therapeutic potential through pathway regulation, yet its ...
The small molecules in question are ASTX029, an ERK1/2 inhibitor that has completed a phase 2 study, and ASTX295 an MDM2 antagonist that has undergone a phase 1 trial. Both candidates have ...
Moreover, GK-Ae increased the levels of both p53 and its downstream targets p21 and BAX, and promoted apoptosis of cancer cells. Conclusion: These results demonstrate the potential of combinatorial ...
In 2024, PAL recorded its fourth consecutive year of profitable operations with a net income of P10.2 billion, although this marked a 51 percent decline from its record-high net income of P21 ...
The presence of Δ133p53 or Δ160p53 significantly reduced the binding of FLp53 to the p21 promoter, which has the highest affinity for FLp53, while having minimal impact on its interaction with the ...
Department of Cell and Molecular Biology, Uppsala University, Biomedical Center, Uppsala, Sweden Department of Medical Biochemistry and Microbiology, Uppsala University, Biomedical Center, Uppsala, ...
School of Pharmaceutical Science and Technology, Tianjin University, 92 Weijin Road, Nankai District, Tianjin 300072, China ...
Furthermore, TBMS-1-induced molecular events were associated with mitochondria-induced intrinsic apoptosis and p21/cyclin B1/cell division cycle 2 (p21/Cyc B1/cdc2) complex-related G2/M cell cycle ...